跳转到主要内容

研究 和 discovery efforts battling COVID-19 和 beyond

With extensive expertise in virology, small molecule 和 antibody therapeutics,
AbbVie scientists bring decades of experience to the fight. 

“世界从未经历过如此严重的危机，人们正依靠科学来回应这一召唤. AbbVie’s scientists underst和 the stakes 和 are using our decades of expertise to help." 
汤姆·哈德逊,米.D.高级副总裁R&D, chief scientific officer, AbbVie

利用我们的专业知识

AG体育的科学专业知识是我们帮助抗击COVID-19的重要资产. 我们的R&D team has reviewed our compounds, 现有药物和管道资产评估其作为潜在治疗药物的疗效，同时建立和加速发现努力.

And we’re working with global health authorities, government health officials, 大学和其他生物制药公司帮助应对大流行的医学影响.

活性关系

AG体育正在参与由美国国立卫生研究院和美国国立卫生研究院基金会牵头的COVID-19加速治疗干预措施和疫苗(ACTIV)伙伴关系。. 这一合作关系汇集了十多家领先的生物制药公司，包括美国制药公司.S. Centers for Disease Control 和 Prevention (CDC), the U.S. Food 和 Drug Administration (FDA), 和欧洲药品管理局(EMA)，以制定一项协调研究应对COVID-19大流行的国际战略. AbbVie assets are being studied as part of the ACTIV-5大效应试验 和 ACTIV-1免疫调节剂 试验. 了解更多.

COVID R&D联盟

AbbVie is proud to be part of the COVID R&D联盟将与其他业内人士一道，为抗击新冠肺炎疫情提供帮助. 在一起 we are working to identify, 研究, 和 accelerate the most promising therapeutic drug c和idates.

抗体的研究

AbbVie is working with Harbour BioMed, 乌得勒支大学, 和伊拉斯谟医疗中心共同开发一种新型抗体疗法，以预防和治疗COVID-19. The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11, which targets the conserved domain of the spike protein of SARS-CoV-2, the virus that causes COVID-19. 了解更多.

 

Ibrutinib研究

AbbVie has initiated a Phase 2 研究 of ibrutinib in patients with COVID-19 infection. 这项研究的目的是确定伊布替尼是否可以通过减少被称为细胞因子风暴的免疫反应来改善患者的预后，该免疫反应是导致COVID-19发病率和死亡率的原因.

保健协会

Along with industry partners, AbbVie has joined the Innovative Medicines Initiative’s Corona Accelerated R&该项目旨在支持针对COVID-19的靶向药物的研究和发现. 通过我们内部的研究和与外部机构和学术界的合作, 我们致力于开发广泛中和的抗covid -19抗体和小分子抗病毒药物, which we will bring into clinical 试验s as quickly as possible. 了解更多.

Harvard University partnership

AG体育(AbbVie)和哈佛大学(Harvard University)将启动一个3000万美元的研究联盟，以研究和开发对抗突发病毒感染的新疗法. 合作的具体重点将是由冠状病毒和导致出血热的病毒引起的感染. 在一起, AG体育和哈佛医学院的目标是快速整合基础生物学到病毒疾病的临床前和临床新疗法的开发，解决各种治疗方式. 了解更多.

有关的故事

合作伙伴关系 during a p和emic: 3 reasons why they’re critical

全球 partnerships help give scientists an edge against tough diseases 和 viruses, from COVID-19 to autoimmune disorders.

阅读更多

Helping solve for the next COVID

Working to treat diseases that don’t even exist yet.

阅读更多

How AbbVie is bringing antiviral expertise to the COVID-19 battle

At the first sign of the p和emic, AbbVie began evaluating ways to help, including accelerating discovery efforts 和 external collaborations.

阅读更多